Real-World Use of Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma: A Systematic Review

Abstract

Belantamab mafodotin is an antibody drug conjugate directed against B-cell maturation antigen and was approved by the Food and Drug Administration under accelerated approval for use in the US in August 2020 for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug. In November 2022 belantamab mafodotin was withdrawn from the US market after failure of a required confirmatory trial. In our review, we provide a systematic review on the use of belantamab mafodotin efficacy and safety in a real-world setting.